Leukemia, B-Cell
Information
- Disease name
- Leukemia, B-Cell
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01087294 | Completed | Phase 1 | Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | August 4, 2010 | April 2, 2024 |
| NCT03229200 | Enrolling by invitation | Phase 4 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | May 22, 2017 | July 2, 2027 |
| NCT02473757 | Enrolling by invitation | Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies | September 24, 2015 | August 1, 2050 | |
| NCT06345027 | Not yet recruiting | Phase 1 | CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY) | April 1, 2024 | April 1, 2042 |
| NCT06209671 | Not yet recruiting | Phase 1 | INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia | January 15, 2024 | January 15, 2026 |
| NCT04271800 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma | December 1, 2019 | July 1, 2024 |
| NCT05619861 | Recruiting | N/A | CAR-T Cells in the Treatment of Malignant Hematological Tumors | April 27, 2020 | December 26, 2023 |
| NCT05362773 | Recruiting | Phase 1 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | July 13, 2022 | March 2025 |
| NCT05254743 | Recruiting | Phase 3 | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | July 22, 2022 | August 2028 |
| NCT05010564 | Recruiting | Phase 1 | Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL) | July 18, 2023 | March 29, 2040 |
| NCT04649983 | Recruiting | Phase 1/Phase 2 | CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | September 1, 2019 | July 1, 2024 |
| NCT04648475 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | August 25, 2020 | July 1, 2024 |
| NCT03614858 | Recruiting | Phase 1/Phase 2 | CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. | September 1, 2017 | December 31, 2025 |
| NCT04090268 | Recruiting | N/A | Precision Exercise in Children With Malignant Hemopathies | April 3, 2017 | April 3, 2026 |
| NCT04271410 | Recruiting | Phase 1/Phase 2 | CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma | June 1, 2019 | July 1, 2024 |
| NCT02848911 | Terminated | Phase 1 | Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL | October 2016 | April 2019 |
| NCT02518750 | Terminated | Phase 2 | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma | November 23, 2016 | March 11, 2018 |
| NCT04439721 | Unknown status | Early Phase 1 | γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse | May 1, 2020 | May 1, 2021 |
| NCT03599375 | Unknown status | Phase 1 | Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia | May 1, 2019 | December 30, 2021 |
| NCT03598179 | Unknown status | Phase 2 | XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects | June 1, 2018 | July 1, 2020 |
| NCT03564977 | Unknown status | N/A | CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation | July 15, 2018 | June 15, 2020 |
| NCT03564470 | Unknown status | Phase 2/Phase 3 | Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL | February 14, 2016 | August 30, 2023 |
| NCT02672501 | Unknown status | Phase 1/Phase 2 | A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia | January 2016 | December 2019 |
| NCT02813837 | Unknown status | N/A | Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies | June 2015 | July 2021 |
| NCT03605589 | Withdrawn | Phase 1 | Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma | September 27, 2018 | January 2022 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D015448